

Criteria-Based Consultation Prescribing Program

CRITERIA FOR DRUG COVERAGE

Larotrectinib (Vitrakvi)

Initiation (new start) criteria: Non-formulary **larotrectinib (Vitrakvi)** will be covered on the prescription drug benefit when the following criteria are met:

- Known or predicted intolerance to formulary alternative **entrectinib (Rozlytrek)**
- Any solid tumor with a neurotrophic tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation
- Tumor is metastatic **-OR-** surgical resection is likely to result in severe morbidity
- Patient has progressed following treatment or has no satisfactory alternative therapies available

Criteria for current Kaiser Permanente members already taking the medication who have not been reviewed previously: Non-formulary **larotrectinib (Vitrakvi)** will be covered on the prescription drug benefit when the following criteria are met:

- Known or predicted intolerance to formulary alternative **entrectinib (Rozlytrek)**
- Any solid tumor with a neurotrophic tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation

Criteria for new members entering Kaiser Permanente already taking the medication who have not been reviewed previously: Non-formulary **larotrectinib (Vitrakvi)** will be covered on the prescription drug benefit when the following criteria are met:

- Known or predicted intolerance to formulary alternative **entrectinib (Rozlytrek)**
- Any solid tumor with a neurotrophic tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation